HHS Nominee Price's Stock Picks To Surface At Confirmation Hearings
Questions about US Health and Human Services Secretary nominee Tom Price's investments over the last year – including in Zimmer Biomet – and overlapping legislation he has introduced are likely to be raised at confirmation hearing before the Senate HELP Committee this week. However, Zimmer Biomet and other device firms have been trying to profit from the business models that Price opposes.
You may also be interested in...
US Health and Human Service Secretary Tom Price resigned Sept. 29 following controversy over free flights on military and private jets. Price, a former orthopedic surgeon and Georgia congressman, had initiated a reset of Obama-era payment reforms and oversaw an active FDA commissioner during his short tenure.
Senate Finance Committee Ranking Member Ron Wyden led other panel Democrats in boycotting a planned Jan. 31 vote on the confirmation of Rep. Tom Price as HHS Secretary. Wyden said the nominee "misled the public" and held back information on discounted shares of an Australian biomedical firm he bought. Committee Chair Orrin Hatch, R-Utah, was surprised by the setback to President Trump's nominee, and swore to bring Senate Democrats back to the committee to "do their job.”
Sen. Chuck Grassley, R-Iowa, urged US Department of Health and Human Services secretary nominee Tom Price to preserve the "Open Payments" database that was established by Grassley's Physician Payment Sunshine Act, even if the Affordable Care Act, by which the Sunshine law was enacted, is repealed.